Trial Profile
A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Vamorolone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors ReveraGen BioPharma
- 20 May 2020 Results of exposure-response relationships of vamorolone in three studies (VBP15-001, VBP15-002 & VBP15-003) boys with Duchenne muscular dystrophy, published in the Journal of Clinical Pharmacology.
- 11 Feb 2019 PK modelling results of this and other phase 2a study published in the Journal of Clinical Pharmacology.
- 10 May 2016 Status changed from recruiting to completed.